What are the findings of the GEMINI-ACS-1 trial?
The GEMINI-ACS-1 trial was a randomized trial that compared the safety of rivaroxaban and aspirin with either clopidogrel or ticagrelor in acute coronary patients. The trial found that 3,037 patients with ACS were randomly assigned to either aspirin 100 mg or rivaroxaban 2.5 mg bid, and the subsequent choice of clopidogrel (44%) or ticagrelor (in 56%) during trial conduct was nonrandomized.